Clinical Trial Update: A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer is currently recruiting. The sponsor is Syncromune, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• SYNC-T Therapy SV-102 (SV-102)

Snippet

Sponsor: Syncromune, Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING